Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71,994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Sarrazin C, et al. Among authors: zhou y. Gastroenterology. 2007 May;132(5):1767-77. doi: 10.1053/j.gastro.2007.02.037. Epub 2007 Feb 21. Gastroenterology. 2007. PMID: 17484874 Clinical Trial.
In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. Jiang M, et al. Among authors: zhou y. Antimicrob Agents Chemother. 2013 Dec;57(12):6236-45. doi: 10.1128/AAC.01578-13. Epub 2013 Oct 7. Antimicrob Agents Chemother. 2013. PMID: 24100495 Free PMC article.
Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.
Barbotte L, Ahmed-Belkacem A, Chevaliez S, Soulier A, Hézode C, Wajcman H, Bartels DJ, Zhou Y, Ardzinski A, Mani N, Rao BG, George S, Kwong A, Pawlotsky JM. Barbotte L, et al. Among authors: zhou y. Antimicrob Agents Chemother. 2010 Jun;54(6):2681-3. doi: 10.1128/AAC.01796-09. Epub 2010 Apr 5. Antimicrob Agents Chemother. 2010. PMID: 20368394 Free PMC article.
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. Byrn RA, et al. Among authors: zhou y. Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29. Antimicrob Agents Chemother. 2015. PMID: 25547360 Free PMC article.
Treatment of HCV infection by targeting microRNA.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Janssen HL, et al. Among authors: zhou y. N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27. N Engl J Med. 2013. PMID: 23534542 Free article. Clinical Trial.
71,994 results
You have reached the last available page of results. Please see the User Guide for more information.